Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 6/20 | 0.50 |
| ▸ | DRD4 | P21917 | 4/20 | 0.50 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.50 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.50 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.50 |
| ▸ | DHFR | P00374 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | PHGDH | O43175 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6095533 | 0.79 | DRD4 (0.56) | GRM2DRD4ALDH1A2ALDH1A1ALDH2 | |
| SCHEMBL7701573 | 0.77 | GRM2 (0.48) | GRM2DRD4ALDH1A2ALDH1A1ALDH2 | |
| SCHEMBL15748232 | 0.71 | SIGMAR1 (0.59) | DRD2OPRM1PHGDHHTR7DRD3 | |
| SCHEMBL17471515 | 0.70 | DRD3 (0.56) | GRM2DRD4ALDH1A1DRD2TP53 | |
| SCHEMBL15748175 | 0.70 | SIGMAR1 (0.58) | DRD2OPRM1HTR7DRD3 | |
| SCHEMBL6095407 | 0.69 | DRD4 (0.64) | GRM2DRD4DRD2MAPTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL7695313 | 0.68 | KDM4E (0.57) | ALDH1A1DHFRDRD2TP53KDM4E | |
| SCHEMBL11925196 | 0.68 | DRD3 (0.54) | GRM2DRD4ALDH1A1DRD2TP53 | |
| SCHEMBL6864697 | 0.68 | SIGMAR1 (0.76) | DRD4ALDH1A1DRD2TP53KDM4E | |
| SCHEMBL7859184 | 0.68 | PHGDH (0.58) | GRM2DRD4ALDH1A1DHFRDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030150-B2 | Benzimidazole compounds and antiviral uses thereof | TRIMERIS, INC. | 2006-04-18 | — | — | US | claimed |
| US-20030119754-A1 | Benzimidazole compounds and antiviral uses thereof | TRIMERIS, INC. | 2003-06-26 | — | — | US | claimed |
| WO-2002092575-A1 | BENZIMIDAZOLE COMPOUNDS AND ANTIVIRAL USES THEREOF | TRIMERIS, INC. (US) | 2002-11-21 | — | — | WO | claimed |
| US-20060142365-A1 | Benzimidazole compounds and antiviral uses thereof | TRIMERIS, INC. | 2006-06-29 | — | — | US | disclosed |
| US-7030150-B2 | Benzimidazole compounds and antiviral uses thereof | TRIMERIS, INC. | 2006-04-18 | — | — | US | disclosed |
| US-20030119754-A1 | Benzimidazole compounds and antiviral uses thereof | TRIMERIS, INC. | 2003-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142365-A1 | Benzimidazole compounds and antiviral uses thereof | MAVS, ZC3HAV1, TIMM13 | GRM2 4337/4885DRD4 1827/4885ALDH1A2 2701/4885 |
| US-20030119754-A1 | Benzimidazole compounds and antiviral uses thereof | MAVS, ZC3HAV1, TIMM13 | GRM2 4337/4885DRD4 1827/4885ALDH1A2 2701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.